1762 related articles for article (PubMed ID: 26041750)
1. Faecal immunochemical tests versus guaiac faecal occult blood tests: what clinicians and colorectal cancer screening programme organisers need to know.
Tinmouth J; Lansdorp-Vogelaar I; Allison JE
Gut; 2015 Aug; 64(8):1327-37. PubMed ID: 26041750
[TBL] [Abstract][Full Text] [Related]
2. Superior diagnostic performance of faecal immunochemical tests for haemoglobin in a head-to-head comparison with guaiac based faecal occult blood test among 2235 participants of screening colonoscopy.
Brenner H; Tao S
Eur J Cancer; 2013 Sep; 49(14):3049-54. PubMed ID: 23706981
[TBL] [Abstract][Full Text] [Related]
3. Switching from guaiac to immunochemical faecal occult blood test increases participation and diagnostic yield of colorectal cancer screening.
Bretagne JF; Piette C; Cosson M; Durand G; Lièvre A
Dig Liver Dis; 2019 Oct; 51(10):1461-1469. PubMed ID: 31151896
[TBL] [Abstract][Full Text] [Related]
4. Seasonal variations do not affect the superiority of fecal immunochemical tests over guaiac tests for colorectal cancer screening.
Chausserie S; Levillain R; Puvinel J; Ferrand O; Ruiz A; Raginel T; Lantieri O; Launoy G; Guittet L
Int J Cancer; 2015 Apr; 136(8):1827-34. PubMed ID: 25195670
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness of the faecal immunochemical test at a range of positivity thresholds compared with the guaiac faecal occult blood test in the NHS Bowel Cancer Screening Programme in England.
Murphy J; Halloran S; Gray A
BMJ Open; 2017 Oct; 7(10):e017186. PubMed ID: 29079605
[TBL] [Abstract][Full Text] [Related]
6. Screening for colorectal cancer: randomised trial comparing guaiac-based and immunochemical faecal occult blood testing and flexible sigmoidoscopy.
Hol L; van Leerdam ME; van Ballegooijen M; van Vuuren AJ; van Dekken H; Reijerink JC; van der Togt AC; Habbema JD; Kuipers EJ
Gut; 2010 Jan; 59(1):62-8. PubMed ID: 19671542
[TBL] [Abstract][Full Text] [Related]
7. Comparison of a brush-sampling fecal immunochemical test for hemoglobin with a sensitive guaiac-based fecal occult blood test in detection of colorectal neoplasia.
Smith A; Young GP; Cole SR; Bampton P
Cancer; 2006 Nov; 107(9):2152-9. PubMed ID: 16998938
[TBL] [Abstract][Full Text] [Related]
8. Performance improvements of stool-based screening tests.
van Dam L; Kuipers EJ; van Leerdam ME
Best Pract Res Clin Gastroenterol; 2010 Aug; 24(4):479-92. PubMed ID: 20833351
[TBL] [Abstract][Full Text] [Related]
9. Short term outcomes of the first round of a pilot colorectal cancer screening programme with guaiac based faecal occult blood test.
Denis B; Ruetsch M; Strentz P; Vogel JY; Guth F; Boyaval JM; Pagnon X; Ebelin JF; Gendre I; Perrin P
Gut; 2007 Nov; 56(11):1579-84. PubMed ID: 17616542
[TBL] [Abstract][Full Text] [Related]
10. Colorectal cancer screening with the addition of flexible sigmoidoscopy to guaiac-based faecal occult blood testing: a French population-based controlled study (Wintzenheim trial).
Denis B; Gendre I; Aman F; Ribstein F; Maurin P; Perrin P
Eur J Cancer; 2009 Dec; 45(18):3282-90. PubMed ID: 19665368
[TBL] [Abstract][Full Text] [Related]
11. Guaiac-based faecal occult blood tests versus faecal immunochemical tests for colorectal cancer screening in average-risk individuals.
Grobbee EJ; Wisse PHA; Schreuders EH; van Roon A; van Dam L; Zauber AG; Lansdorp-Vogelaar I; Bramer W; Berhane S; Deeks JJ; Steyerberg EW; van Leerdam ME; Spaander MC; Kuipers EJ
Cochrane Database Syst Rev; 2022 Jun; 6(6):CD009276. PubMed ID: 35665911
[TBL] [Abstract][Full Text] [Related]
12. Screening for colorectal cancer: comparison of perceived test burden of guaiac-based faecal occult blood test, faecal immunochemical test and flexible sigmoidoscopy.
Hol L; de Jonge V; van Leerdam ME; van Ballegooijen M; Looman CW; van Vuuren AJ; Reijerink JC; Habbema JD; Essink-Bot ML; Kuipers EJ
Eur J Cancer; 2010 Jul; 46(11):2059-66. PubMed ID: 20621736
[TBL] [Abstract][Full Text] [Related]
13. Experience with a two-tier reflex gFOBT/FIT strategy in a national bowel screening programme.
Fraser CG; Digby J; McDonald PJ; Strachan JA; Carey FA; Steele RJ
J Med Screen; 2012 Mar; 19(1):8-13. PubMed ID: 22156144
[TBL] [Abstract][Full Text] [Related]
14. Interval cancers in a national colorectal screening programme based on faecal immunochemical testing: Implications for faecal haemoglobin concentration threshold and sex inequality.
Clark GR; Godfrey T; Purdie C; Strachan J; Carey FA; Fraser CG; Steele RJ
J Med Screen; 2024 Mar; 31(1):21-27. PubMed ID: 37469171
[TBL] [Abstract][Full Text] [Related]
15. Increased uptake and improved outcomes of bowel cancer screening with a faecal immunochemical test: results from a pilot study within the national screening programme in England.
Moss S; Mathews C; Day TJ; Smith S; Seaman HE; Snowball J; Halloran SP
Gut; 2017 Sep; 66(9):1631-1644. PubMed ID: 27267903
[TBL] [Abstract][Full Text] [Related]
16. Colonoscopy-controlled intra-individual comparisons to screen relevant neoplasia: faecal immunochemical test vs. guaiac-based faecal occult blood test.
Oort FA; Terhaar Sive Droste JS; Van Der Hulst RW; Van Heukelem HA; Loffeld RJ; Wesdorp IC; Van Wanrooij RL; De Baaij L; Mutsaers ER; van der Reijt S; Coupe VM; Berkhof J; Bouman AA; Meijer GA; Mulder CJ
Aliment Pharmacol Ther; 2010 Feb; 31(3):432-9. PubMed ID: 19878150
[TBL] [Abstract][Full Text] [Related]
17. Immunochemical testing of individuals positive for guaiac faecal occult blood test in a screening programme for colorectal cancer: an observational study.
Fraser CG; Matthew CM; Mowat NA; Wilson JA; Carey FA; Steele RJ
Lancet Oncol; 2006 Feb; 7(2):127-31. PubMed ID: 16455476
[TBL] [Abstract][Full Text] [Related]
18. Benefits of switching from guaiac-based faecal occult blood to faecal immunochemical testing: experience from the Wallonia-Brussels colorectal cancer screening programme.
Guo F; De Brabander I; Francart J; Candeur M; Polus M; Van Eycken L; Brenner H
Br J Cancer; 2020 Mar; 122(7):1109-1117. PubMed ID: 32066910
[TBL] [Abstract][Full Text] [Related]
19. Screening for colorectal neoplasms with new fecal occult blood tests: update on performance characteristics.
Allison JE; Sakoda LC; Levin TR; Tucker JP; Tekawa IS; Cuff T; Pauly MP; Shlager L; Palitz AM; Zhao WK; Schwartz JS; Ransohoff DF; Selby JV
J Natl Cancer Inst; 2007 Oct; 99(19):1462-70. PubMed ID: 17895475
[TBL] [Abstract][Full Text] [Related]
20. Gender-specific cut-offs in colorectal cancer screening with FIT: Increased compliance and equal positivity rate.
Blom J; Löwbeer C; Elfström KM; Sventelius M; Öhman D; Saraste D; Törnberg S
J Med Screen; 2019 Jun; 26(2):92-97. PubMed ID: 30336730
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
